Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2013-10-01 Environmental & Social …
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Medivir meddelar att data för Simeprevir kommer presenteras på den kommande internationella leverkongressen AASLD
Environmental & Social Information Classification · 99% confidence The document is a press release dated October 1, 2013, announcing that data regarding the drug Simeprevir will be presented at the upcoming international liver congress, AASLD (Annual Meeting of the American Association for the Study of Liver Diseases). It details the specific poster presentations and authors. This is not a full financial report (10-K or IR), an earnings release (ER), or a management discussion (MDA). It is an announcement concerning scientific data presentation, which falls under general investor relations or regulatory communication. Since it is a specific announcement about scientific data presentation at a conference, and not a general regulatory filing (RNS) or a presentation document itself (IP), it is best classified as a general Investor Relations announcement. However, given the specific categories, it is an announcement about company activities and data dissemination. It is not a proxy statement (PSI), dividend notice (DIV), or management change (MANG). Since it is a press release announcing future presentation of scientific data, it functions as an Investor Relations update. If a specific 'Scientific Update' category existed, it would fit there. Lacking that, and given it's a formal announcement to investors about data dissemination, it aligns most closely with general Investor Relations communication, which often defaults to RNS if no other category fits perfectly. However, since it is a formal press release detailing specific company news (data presentation), and not just a generic regulatory filing, I will check if it fits 'RPA' (Report Publication Announcement). It is announcing the publication/presentation of data, not the publication of a formal financial report. Therefore, RNS (Regulatory Filings - general/miscellaneous) is the most appropriate fallback for a specific, non-financial, non-management press release about scientific updates.
2013-10-01 Swedish
Medivir announces that Simeprevir data will be presented at the upcoming AASLD meeting
Regulatory Filings Classification · 85% confidence The document is a press release dated October 1, 2013, announcing that data regarding the investigational drug simeprevir will be presented at the upcoming AASLD Annual Meeting (a scientific/investor event). It details the specific poster presentations and sessions. This is not a formal regulatory filing (like 10-K, IR, or ER), nor is it a general investor presentation (IP) or a factsheet (FS). It is an announcement about future scientific/investor-related activity, which fits best under the general category of Investor Relations or Regulatory Filings, but given the context of announcing data presentation at a conference, it is most closely related to investor communication about ongoing research/pipeline progress. Since there is no specific code for 'Conference Presentation Announcement', and it is a general announcement about company activity intended for investors and the public, it falls under the broad 'Regulatory Filings' (RNS) as a miscellaneous announcement, or potentially Investor Presentation (IP) if it were the presentation itself. However, since it is an announcement *about* data being presented elsewhere, RNS is the most appropriate fallback for a non-standard announcement, though it strongly relates to investor information. Given the options, and that it is a press release announcing future events/data, RNS (Regulatory Filings/General Announcement) is the safest classification, as it is not a core financial report or a specific management/director update.
2013-10-01 English
Simeprevir har godkänts i Japan för behandling av kronisk genotyp 1 hepatit C-infektion
Regulatory Filings Classification · 95% confidence The document is a press release dated September 27, 2013, announcing that the drug simeprevir has been approved in Japan for treating Hepatitis C. It details the approval, mentions a milestone payment received by Medivir, describes the drug's mechanism and clinical trial results, and provides company background. This type of announcement, which is a specific, material corporate event update (drug approval and associated payment), does not fit neatly into the defined categories like 10-K (Annual Report), ER (Earnings Release), or CT (Call Transcript). Since it is a specific regulatory/material event announcement that doesn't match a more specific code (like DIV, CAP, or TAR), the most appropriate fallback category is Regulatory Filings (RNS), as it is a general regulatory/material announcement not covered elsewhere.
2013-09-27 Swedish
Simeprevir has been approved in Japan for the treatment of genotype 1 chronic hepatitis C infection
Regulatory Filings Classification · 95% confidence The document is titled "Press Release" and announces a specific corporate event: the approval of the drug simeprevir in Japan by the Japanese Ministry of Health, Labour and Welfare (MHLW). It details the significance of the approval, the triggering of a milestone payment (€5m to Medivir), and provides background information on the drug and the disease context in Japan. This format—a brief, timely announcement of a significant business/regulatory event—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a management discussion (MDA), or a transcript (CT), and it is a specific, material announcement, it fits best as an Earnings Release (ER) if it were tied to quarterly results, or more generally as a Regulatory Filing (RNS) for non-standard material news. Given the content is a specific, material business development (drug approval triggering payment) rather than a summary of financial performance metrics, RNS is a strong candidate. However, many companies use ER for significant non-earnings news releases. Comparing the options, this is a material announcement that doesn't fit the specific financial report codes. It is not a proxy statement (DEF 14A), dividend notice (DIV), or management change (MANG). Since it is a press release announcing a major regulatory/commercial milestone, and RNS is the general regulatory fallback, I will classify it as RNS, as it is a general regulatory announcement that doesn't fit the more specific financial report types.
2013-09-27 English
Medivir anordnar kapitalmarknadsdag den 10 oktober 2013
Regulatory Filings Classification · 99% confidence The document is a press release dated September 18, 2013, announcing that Medivir AB will host a 'kapitalmarknadsdag' (Capital Markets Day) on October 10, 2013. This event is explicitly for journalists, analysts, and investors, where the CEO and other executives will provide updates on the company's operations, products, and R&D projects. This type of event, focused on presenting strategy and detailed business/financial updates to the investment community, aligns best with the Investor Presentation (IP) category, as it is a structured presentation event for investors. Although it is an announcement of an event, the content describes the nature of the presentation itself, which is a detailed investor briefing, making 'IP' a stronger fit than a general 'RPA' or 'RNS'.
2013-09-18 Swedish
Medivir Capital Markets Day on 10 October 2013
Report Publication Announcement Classification · 99% confidence The document is a press release dated September 18, 2013, announcing a future 'Capital Markets Day' scheduled for October 10, 2013. It details the time, venue, participants (CEO and other executives), and registration instructions for media, analysts, and investors. This announcement is specifically about an upcoming event designed to update investors on operations, products, and R&D projects. This type of forward-looking event announcement, which is not a formal financial report (like 10-K or IR) or a transcript of a call, fits best under the category of Investor Presentation (IP) or a general announcement. Since it is an announcement *about* an event where presentations will be given, and it is not the presentation itself, it is closest to an Investor Presentation announcement, but given the options, it is an announcement regarding an event aimed at investors and analysts to discuss strategy and pipeline, which aligns closely with the purpose of an Investor Presentation (IP). However, since it is purely an announcement of the event logistics, and not the presentation materials themselves, it could also be considered a Regulatory Filing (RNS) if no better fit exists. Given the content focuses entirely on an event where strategy and pipeline will be discussed (similar to an Investor Presentation), and it is a short announcement, I will check the definitions. It is not a standard ER, AR, or 10-K. It is an announcement of an event where an Investor Presentation will likely occur. If the document itself were the presentation slides, it would be IP. As it is the invitation/logistics announcement, it is a general announcement. The closest fit among the specific categories related to investor communication about strategy/pipeline is 'Investor Presentation' (IP), even though it's the announcement of the event rather than the presentation itself. If we strictly follow the 'Menu vs Meal' rule, this is an announcement, not the meal. Since there is no specific 'Event Announcement' code, and it's not a standard regulatory filing like a DIV or DIRS, I will classify it as an Investor Presentation (IP) as it pertains directly to the content to be presented at that investor-focused event, or RNS as a fallback. Given the high specificity of the event (Capital Markets Day), IP is the most contextually relevant category for the *subject matter* being announced.
2013-09-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.